57 related articles for article (PubMed ID: 21177409)
21. Oncogenic role of the Notch pathway in primary liver cancer.
Lu J; Xia Y; Chen K; Zheng Y; Wang J; Lu W; Yin Q; Wang F; Zhou Y; Guo C
Oncol Lett; 2016 Jul; 12(1):3-10. PubMed ID: 27347091
[TBL] [Abstract][Full Text] [Related]
22. Spanning the genomics era: the vital role of a single institution biorepository for childhood cancer research over a decade.
Zhou L; Catchpoole D
Transl Pediatr; 2015 Apr; 4(2):93-106. PubMed ID: 26835365
[TBL] [Abstract][Full Text] [Related]
23. Hes1 triggers epithelial-mesenchymal transition (EMT)-like cellular marker alterations and promotes invasion and metastasis of nasopharyngeal carcinoma by activating the PTEN/AKT pathway.
Wang SC; Lin XL; Wang HY; Qin YJ; Chen L; Li J; Jia JS; Shen HF; Yang S; Xie RY; Wei F; Gao F; Rong XX; Yang J; Zhao WT; Zhang TT; Shi JW; Yao KT; Luo WR; Sun Y; Xiao D
Oncotarget; 2015 Nov; 6(34):36713-30. PubMed ID: 26452025
[TBL] [Abstract][Full Text] [Related]
24. Hedgehog/Patched-associated rhabdomyosarcoma formation from delta1-expressing mesodermal cells.
Nitzki F; Cuvelier N; Dräger J; Schneider A; Braun T; Hahn H
Oncogene; 2016 Jun; 35(22):2923-31. PubMed ID: 26387541
[TBL] [Abstract][Full Text] [Related]
25. SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation.
Casini N; Forte IM; Mastrogiovanni G; Pentimalli F; Angelucci A; Festuccia C; Tomei V; Ceccherini E; Di Marzo D; Schenone S; Botta M; Giordano A; Indovina P
Oncotarget; 2015 May; 6(14):12421-35. PubMed ID: 25762618
[TBL] [Abstract][Full Text] [Related]
26. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
[TBL] [Abstract][Full Text] [Related]
27. Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.
Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Wu J; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Lyalin D
Pediatr Blood Cancer; 2014 Aug; 61(8):1493-6. PubMed ID: 24664981
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory stress and sarcomagenesis: a vicious interplay.
Radons J
Cell Stress Chaperones; 2014 Jan; 19(1):1-13. PubMed ID: 24046208
[TBL] [Abstract][Full Text] [Related]
29. Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling.
Guijarro MV; Dahiya S; Danielson LS; Segura MF; Vales-Lara FM; Menendez S; Popiolek D; Mittal K; Wei JJ; Zavadil J; Cordon-Cardo C; Pandolfi PP; Hernando E
Am J Pathol; 2013 Jun; 182(6):2015-27. PubMed ID: 23708211
[TBL] [Abstract][Full Text] [Related]
30. Notch signaling in pediatric soft tissue sarcomas.
Rota R; Ciarapica R; Miele L; Locatelli F
BMC Med; 2012 Nov; 10():141. PubMed ID: 23158439
[TBL] [Abstract][Full Text] [Related]
31. Notch-mediated induction of N-cadherin and α9-integrin confers higher invasive phenotype on rhabdomyosarcoma cells.
Masià A; Almazán-Moga A; Velasco P; Reventós J; Torán N; Sánchez de Toledo J; Roma J; Gallego S
Br J Cancer; 2012 Oct; 107(8):1374-83. PubMed ID: 22976797
[TBL] [Abstract][Full Text] [Related]
32. RBPJ is a novel target for rhabdomyosarcoma therapy.
Nagao H; Setoguchi T; Kitamoto S; Ishidou Y; Nagano S; Yokouchi M; Abematsu M; Kawabata N; Maeda S; Yonezawa S; Komiya S
PLoS One; 2012; 7(7):e39268. PubMed ID: 22792167
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapies in sarcomas: challenging the challenge.
Martín Liberal J; Lagares-Tena L; Sáinz-Jaspeado M; Mateo-Lozano S; García Del Muro X; Tirado OM
Sarcoma; 2012; 2012():626094. PubMed ID: 22701332
[TBL] [Abstract][Full Text] [Related]
34. Notch, wnt, and hedgehog pathways in rhabdomyosarcoma: from single pathways to an integrated network.
Roma J; Almazán-Moga A; Sánchez de Toledo J; Gallego S
Sarcoma; 2012; 2012():695603. PubMed ID: 22550422
[TBL] [Abstract][Full Text] [Related]
35. New therapeutic targets in soft tissue sarcoma.
Demicco EG; Maki RG; Lev DC; Lazar AJ
Adv Anat Pathol; 2012 May; 19(3):170-80. PubMed ID: 22498582
[TBL] [Abstract][Full Text] [Related]
36. Notch: a key regulator of tumor angiogenesis and metastasis.
Garcia A; Kandel JJ
Histol Histopathol; 2012 Feb; 27(2):151-6. PubMed ID: 22207549
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo.
Raimondi L; Ciarapica R; De Salvo M; Verginelli F; Gueguen M; Martini C; De Sio L; Cortese G; Locatelli M; Dang TP; Carlesso N; Miele L; Stifani S; Limon I; Locatelli F; Rota R
Cell Death Differ; 2012 May; 19(5):871-81. PubMed ID: 22117196
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
Belyea BC; Naini S; Bentley RC; Linardic CM
Clin Cancer Res; 2011 Dec; 17(23):7324-36. PubMed ID: 21948088
[TBL] [Abstract][Full Text] [Related]
39. Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro.
Roma J; Masià A; Reventós J; Sánchez de Toledo J; Gallego S
Clin Cancer Res; 2011 Feb; 17(3):505-13. PubMed ID: 21177409
[TBL] [Abstract][Full Text] [Related]
40. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.
Lewis HD; Leveridge M; Strack PR; Haldon CD; O'neil J; Kim H; Madin A; Hannam JC; Look AT; Kohl N; Draetta G; Harrison T; Kerby JA; Shearman MS; Beher D
Chem Biol; 2007 Feb; 14(2):209-19. PubMed ID: 17317574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
